Siemens Healthineers’ solutions touch cancer patients along their entire journey
Lung cancer screening and diagnosis
Treating late-stage lung cancer is extremely challenging. However, lung cancer treatment can be significantly more effective if the disease is detected earlier in stage
I or II, before the onset of symptoms when the disease is still localized. This emphasizes the benefit to establish screening programs for earlier detection. Precise lung cancer staging of lymph node involvement and distant metastases determines the prognosis and is the foundation of adequate therapy selection.
"Lung cancer screening programs could lead to a stage shift"1
Siemens Healthineers portfolio for lung cancer screening
All whole body X-ray SOMATOM computed tomography (CT) and Biograph PET/CT systems are now indicated for low dose lung cancer screening. Siemens Healthineers offers a comprehensive approach to low dose lung cancer screening. This is enabled on most of Siemens Healthineers’ new CT and PET/CT scanners, as well as on the company’s installed base of non-end-of-support scanners, using the standard low-dose lung protocol. Especially the Siemens unique Tin Filter Technology allows very dose efficient native thorax CT imaging.
Increasing diagnostic precision with AI
The AI-Rad Companion, our family of AI-powered, cloud-based augmented workflow solutions, helps you to reduce the burden of basic repetitive tasks and may increase your diagnostic precision when interpreting medical images.We developed the AI-Rad Companion to help you cope with a growing workload. With its deep learning algorithms, AI-Rad Companion automatically highlights abnormalities, segments anatomies, and compares results to reference values.
“Cognitive factors contribute to diagnostic errors in 74% of the cases.”2
Advances in endobronchial biopsy
Endobronchial biopsy is an important diagnostic step to determine malignancy. However, despite procedural advances, the diagnostic yield remains low.3 A study conducted by Avasarala et al. (2020) demonstrated that mobile 3D imaging may help to achieve high targeting rates with reasonable cost.4
Minimally & non-invasive treatments for lung cancer
With the implementation of lung cancer screening for patients at risk, lung cancer can be detected at an early stage which could significantly improve 5-year survival rates5. Furthermore, minimally-invasive treatment options will come more and more into focus.
Early stage lung cancer imposes challenges on therapy because of the size and location of small lesions and variation between the pre-procedural, static diagnostic image and the changes in the physical, breathing lung encountered during surgery, intervention or radiotherapy.6
Siemens Healthineers provides image-guided solutions for non- and minimally- invasive lung cancer therapy to close this gap. Our vision is to positively impact survival rates, minimize the risk of complications, reduce recurrence rates and improve patients’ quality of life.
iVATS in the Hybrid OR
Sophisticated image guidance enables minimally invasive and highly precise interventions on lungs. Surgeons at the Houston Methodist Medical Center perform iVATS procedures in their hybrid OR.
Behind Direct i4D6
Understand our completely new approach to 4D CT scanning and how we can help you to significantly reduce motion artifacts for precise RT planning.
National Lung Screening Trial Research Team. N Engl J Med 2011;365:395-40
Stage Shift graphic based on:
Bray et al. Global Cancer Statistics 2018;0:1-31.
National Cancer Institute. Cancer stat facts: Lung & bronchus cancer, SEER 18 2010 -2016
National Lung Screening Trial Research Team. N Engl J Med 2011;365:395-409
Page 51. Cognitive and System Factors Contributing to Diagnostic Errors in Radiology American Journal of Roentgenology, 2014
Casal et al. Cone beam computed tomography-guided thin/ultrathin bronchoscopy for diagnosis of peripheral lung nodules: a prospective pilot study. J Thorac Dis 2018
Avasarala et al. Multidimensional Precision Hybrid Mobile 2D/3D C-Arm Assisted Biopsy of Peripheral Lung Nodules. J Bronchol Intervent Pulmonol 2020
Thomas A. et al. 2015 Trends and characteristics of young non-small cell lung cancer patients in the United States. Front Oncol. 2015;5:113
Knight, S.B. et al. 2017 Progress and prospects of early detection in lung cancer. Open Biol. 2017 Sep; 7(9): 170070. doi: 10.1098/rsob.170070
Goldstraw P, et al. 2016. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 11, 39 -51. doi:10.1016/j.jtho.2015.09.009
Requires online mode with Anzai or Varian RGSC.